From Seed Funding to a New Leukemia Drug: How Rally Helped Launch 10+ Years of Discovery

Rally Foundation’s early investment in Mark Chiang’s, M.D., Ph.D, lab at the University of Michigan helped generate the preliminary data needed to secure more than $7 million in funding from the National Institutes of Health and over a decade of continuous federal support. 

Today, Dr. Chiang’s research is exploring a groundbreaking oral drug, RGT-61159, designed to stop cancer-driving proteins before they even form. 

This work could open the door to safer, more targeted treatments for children with hard-to-treat leukemia. 

This is why early-stage research funding matters.
This is the power of philanthropic seed investing.
This is Rally.